Eurofins Scientific SE
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $56.98
- Today's High:
- $58.12
- Open Price:
- $57.448
- 52W Low:
- $54.75
- 52W High:
- $91.3469
- Prev. Close:
- $56.98
- Volume:
- 738
Company Statistics
- Market Cap.:
- $12.67 billion
- Book Value:
- 24.829
- Revenue TTM:
- $6.71 billion
- Operating Margin TTM:
- 13.54%
- Gross Profit TTM:
- $1.53 billion
- Profit Margin:
- 9.09%
- Return on Assets TTM:
- 5.85%
- Return on Equity TTM:
- 12.72%
Company Profile
Eurofins Scientific SE had its IPO on under the ticker symbol ERFSF.
The company operates in the Healthcare sector and Diagnostics & Research industry. Eurofins Scientific SE has a staff strength of 61,379 employees.
Stock update
Shares of Eurofins Scientific SE opened at $57.45 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $56.98 - $58.12, and closed at $56.98.
This is a 0% increase from the previous day's closing price.
A total volume of 738 shares were traded at the close of the day’s session.
In the last one week, shares of Eurofins Scientific SE have slipped by -8.72%.
Eurofins Scientific SE's Key Ratios
Eurofins Scientific SE has a market cap of $12.67 billion, indicating a price to book ratio of 2.722 and a price to sales ratio of 1.948.
In the last 12-months Eurofins Scientific SE’s revenue was $6.71 billion with a gross profit of $1.53 billion and an EBITDA of $1.35 billion. The EBITDA ratio measures Eurofins Scientific SE's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eurofins Scientific SE’s operating margin was 13.54% while its return on assets stood at 5.85% with a return of equity of 12.72%.
In Q2, Eurofins Scientific SE’s quarterly earnings growth was a negative -16.1% while revenue growth was a negative 4.2%.
Eurofins Scientific SE’s PE and PEG Ratio
- Forward PE
- 17.1527
- Trailing PE
- 20.6707
- PEG
- 29.4566
Its diluted EPS in the last 12-months stands at $3.17 per share while it has a forward price to earnings multiple of 17.1527 and a PEG multiple of 29.4566. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eurofins Scientific SE’s profitability.
Eurofins Scientific SE stock is trading at a EV to sales ratio of 2.327 and a EV to EBITDA ratio of 10.6041. Its price to sales ratio in the trailing 12-months stood at 1.948.
Eurofins Scientific SE stock pays annual dividends of $1 per share, indicating a yield of 1.53% and a payout ratio of 32.57%.
Balance sheet and cash flow metrics
- Total Assets
- $10.08 billion
- Total Liabilities
- $1.77 billion
- Operating Cash Flow
- $-237300000.00
- Capital Expenditure
- $124.40 million
- Dividend Payout Ratio
- 32.57%
Eurofins Scientific SE ended 2024 with $10.08 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $10.08 billion while shareholder equity stood at $4.78 billion.
Eurofins Scientific SE ended 2024 with $0 in deferred long-term liabilities, $1.77 billion in other current liabilities, 1900000.00 in common stock, $2.33 billion in retained earnings and $4.52 billion in goodwill. Its cash balance stood at $486.60 million and cash and short-term investments were $486.60 million. The company’s total short-term debt was $213,700,000 while long-term debt stood at $2.71 billion.
Eurofins Scientific SE’s total current assets stands at $2.31 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.05 billion compared to accounts payable of $647.70 million and inventory worth $145.60 million.
In 2024, Eurofins Scientific SE's operating cash flow was $-237300000.00 while its capital expenditure stood at $124.40 million.
Comparatively, Eurofins Scientific SE paid $0.33 in dividends in 2024.
Other key metrics
- Current Trading Price
- $56.98
- 52-Week High
- $91.3469
- 52-Week Low
- $54.75
- Analyst Target Price
- $
Eurofins Scientific SE stock is currently trading at $56.98 per share. It touched a 52-week high of $91.3469 and a 52-week low of $91.3469. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $63.83 and 200-day moving average was $66.3 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 3276.5% of the company’s stock are held by insiders while 3797.1% are held by institutions.
Frequently Asked Questions About Eurofins Scientific SE
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.